132 related articles for article (PubMed ID: 24287663)
1. Weaning from intravenous prostanoids and normalization of hemodynamics by long-term imatinib therapy in severe idiopathic pulmonary arterial hypertension.
Speich R; Treder U; Domenighetti G; Huber LC; Ulrich S
Int J Clin Pharm; 2014 Apr; 36(2):256-60. PubMed ID: 24287663
[TBL] [Abstract][Full Text] [Related]
2. Imatinib as rescue therapy in a patient with pulmonary hypertension associated with Gaucher disease.
Al-Naamani N; Roberts KE; Hill NS; Preston IR
Chest; 2014 Sep; 146(3):e81-e83. PubMed ID: 25180747
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs.
Arita S; Arita N; Hikasa Y
Can Vet J; 2013 Mar; 54(3):255-61. PubMed ID: 23997262
[TBL] [Abstract][Full Text] [Related]
4. The role of imatinib in the treatment of pulmonary hypertension.
Mucke H
Drugs Today (Barc); 2013 Mar; 49(3):203-11. PubMed ID: 23527324
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension.
Chhina MK; Nargues W; Grant GM; Nathan SD
Future Cardiol; 2010 Jan; 6(1):19-35. PubMed ID: 20014985
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension.
Hatano M; Yao A; Shiga T; Kinugawa K; Hirata Y; Nagai R
Int Heart J; 2010 Jul; 51(4):272-6. PubMed ID: 20716845
[TBL] [Abstract][Full Text] [Related]
7. [Imatinib for pulmonary arterial hypertension].
Hoeper MM; Opitz C; Olschewski H; Ulrich S; Speich R; Behr J; Halank M; Wilkens H; Klose H; Lange TJ; Grünig E; Seeger W; Ewert R; Borst MM; Welte T; Rosenkranz S; Ghofrani HA
Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S151-4. PubMed ID: 25489685
[No Abstract] [Full Text] [Related]
8. A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension.
Toba M; Alzoubi A; O'Neill K; Abe K; Urakami T; Komatsu M; Alvarez D; Järvinen TA; Mann D; Ruoslahti E; McMurtry IF; Oka M
Am J Pathol; 2014 Feb; 184(2):369-75. PubMed ID: 24401613
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial Hypertension.
Speich R; Ulrich S; Domenighetti G; Huber LC; Fischler M; Treder U; Breitenstein A
Respiration; 2015; 89(6):515-24. PubMed ID: 26043786
[TBL] [Abstract][Full Text] [Related]
10. Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.
Pitsiou G; Zarogoulidis P; Petridis D; Kioumis I; Lampaki S; Organtzis J; Porpodis K; Papaiwannou A; Tsiouda T; Hohenforst-Schmidt W; Kakolyris S; Syrigos K; Huang H; Li Q; Turner JF; Zarogoulidis K
Drug Des Devel Ther; 2014; 8():1753-63. PubMed ID: 25336919
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension.
Frost AE; Barst RJ; Hoeper MM; Chang HJ; Frantz RP; Fukumoto Y; Galié N; Hassoun PM; Klose H; Matsubara H; Morrell NW; Peacock AJ; Pfeifer M; Simonneau G; Tapson VF; Torres F; Dario Vizza C; Lawrence D; Yang W; Felser JM; Quinn DA; Ghofrani HA
J Heart Lung Transplant; 2015 Nov; 34(11):1366-75. PubMed ID: 26210752
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis?
Erre GL; Pardini S; Cuccuru L; Taras L; Passiu G
Joint Bone Spine; 2015 Jan; 82(1):72-3. PubMed ID: 25059880
[No Abstract] [Full Text] [Related]
13. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension.
ten Freyhaus H; Dumitrescu D; Bovenschulte H; Erdmann E; Rosenkranz S
Clin Res Cardiol; 2009 Apr; 98(4):265-7. PubMed ID: 19219392
[No Abstract] [Full Text] [Related]
14. [Experience with imatinib to treat pulmonary arterial hypertension].
García Hernández FJ; Castillo Palma MJ; González León R; Garrido Rasco R; Ocaña Medina C; Sánchez Román J
Arch Bronconeumol; 2008 Dec; 44(12):689-91. PubMed ID: 19091239
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate for the treatment of pulmonary arterial hypertension.
ten Freyhaus H; Dumitrescu D; Berghausen E; Vantler M; Caglayan E; Rosenkranz S
Expert Opin Investig Drugs; 2012 Jan; 21(1):119-34. PubMed ID: 22074410
[TBL] [Abstract][Full Text] [Related]
16. Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.
Breccia M; Salaroli A; Serrao A; Zacheo I; Saracino R; Alimena G
Leuk Lymphoma; 2014 Jan; 55(1):204-6. PubMed ID: 23586870
[No Abstract] [Full Text] [Related]
17. Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension.
Akagi S; Nakamura K; Miura D; Saito Y; Matsubara H; Ogawa A; Matoba T; Egashira K; Ito H
Int Heart J; 2015 May; 56(3):354-9. PubMed ID: 25902888
[TBL] [Abstract][Full Text] [Related]
18. Recurrence of severe pulmonary hypertension following the removal of a lung allograft.
Grinnan DC; Fairman P; Pinson J
Chest; 2007 Dec; 132(6):2057-8; author reply 2058. PubMed ID: 18079249
[No Abstract] [Full Text] [Related]
19. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
[No Abstract] [Full Text] [Related]
20. [Treatment with imatinib for refractory PAH].
Nakamura K; Akagi S; Sarashina T; Ogawa A; Matsubara H; Ito H
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):173-7. PubMed ID: 24717604
[No Abstract] [Full Text] [Related]
[Next] [New Search]
